Tamoxifen, raloxifene and tibolone decrease risk of invasive breast cancer in healthy women but increase risk of thromboembolism (tamoxifen, raloxifene), endometrial cancer (tamoxifen) or stroke (tibolone)

Evidence-Based Medicine

Volumn 15, Issue 4, 2010, Pages 122-

  Vogel, Victor G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

RALOXIFENE; TAMOXIFEN; TIBOLONE;

BREAST CANCER; CANCER INVASION; CANCER RISK; DRUG EFFICACY; ENDOMETRIUM CANCER; FEMALE; HUMAN; NOTE; OUTCOME ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; THROMBOEMBOLISM; TREATMENT DURATION;

EID: 77955242025     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebm1044     Document Type: Note

References (3)

1. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95:526-32.
2. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-46.
3. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2742-51.